Navigation Links
Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
Date:1/6/2009

CARLSBAD, Calif. and ABBOTT PARK, Ill., Jan. 6 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Abbott (NYSE: ABT) announced today that Abbott has completed its purchase of Ibis Biosciences, Inc., an Isis subsidiary, for a closing purchase price of $175 million. In addition to the closing purchase price, Isis will receive earn out payments from Abbott tied to post-closing sales of Ibis systems, including instruments and assay kits.

Previously, Abbott invested $40 million in Ibis in exchange for approximately 18.6% of Ibis' outstanding equity. This investment, along with the $175 million paid at closing, resulted in a total acquisition price of $215 million plus earn out payments.

"We believe that Abbott is the ideal company to move the Ibis technology into larger commercial markets, such as clinical diagnostics, where Ibis' technology can revolutionize infectious disease detection," said Stanley Crooke, Chairman and CEO of Isis. "With the earn out, Isis and our shareholders will continue to participate in Ibis' success."

"This acquisition will enable Abbott to offer an innovative approach to the detection and characterization of a broad array of pathogens for the management of infectious diseases," said Stafford O'Kelly, Vice President, Molecular Diagnostics, Abbott. "Ibis' unique technology and talented team of scientists will help us continue building a long-term product pipeline for our growing molecular diagnostics business."

About Abbott Molecular

Abbott's molecular diagnostics business, headquartered in Des Plaines, Ill., provides physicians with critical information based on the early detection of pathogens and key changes in patients' genes and chr
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Abbott Begins U.S. Study of XIENCE V(TM) Drug Eluting Stent Designed for Small Vessels
2. Abbott to Present at J.P. Morgan Healthcare Conference
3. (Multimedia Version): Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management
4. Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management
5. Abbott Declares 340th Consecutive Quarterly Dividend
6. Biologic Drugs, Particularly Centocor/Janssen-Cilags Stelara and Abbott/Eisais Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
7. Video: Magic Johnson Foundation and Abbott Call for Greater Prevention, Testing and Treatment on World AIDS Day
8. EGFR-targeting antibody licensed to Abbott
9. Abbott Honored as One of The Deals Most Admired Corporate Dealmakers
10. Abbott to Present at 17th Annual Credit Suisse Health Care Conference
11. Abbott Declares 339th Consecutive Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014 The Little Gym of Houston ... Sunday, July 27 at Discovery Green in downtown Houston. ... Katy, Pearland, Friendswood, Spring, The Woodlands, Sugarland-Missouri City, Kingwood, ... , “We’re thrilled to be attending and performing at ... who owns the Sugarland-Missouri City location. “We believe in ...
(Date:7/25/2014)... AttorneyOne.com, a recognized authority on law, update the website ... Ibuprofen and Oxcarbazepine Tablets . , The FDA ... one lot of Oxcarbazepine Tablets, by American Health Packaging (AHP), ... used for the treatment of certain types of seizures in ... recall is that Lot #142588, Expiration Date, 01/2016 of Ibuprofen ...
(Date:7/25/2014)... Ticket Down is a reliable ... in Berkeley at California Memorial Stadium. With the post-World ... football, the organizers of the 2014 Guinness International Champions Cup ... North America. With teams representing La Liga, English Premier League, ... of the best football players from around the world to ...
(Date:7/25/2014)... 2014 On July 22, 2014, ... client and the nation’s number one provider of ... announced their partnership with TransAct Merchant Solutions’ National ... ISO/MSP of Chase Paymentech Solutions, LLC, which provides ... Companies that are members of TransAct’s National Association ...
(Date:7/25/2014)... Hastings and Hastings, a personal injury ... to personal injury claims, announces free initial consultations. Hastings ... services for those that have been injured as a ... Free initial consultation services gives clients’ greater flexibility in ... personal injury claim . It also offers clients the ...
Breaking Medicine News(10 mins):Health News:The Little Gym of Houston to Attend Houston Family Magazine’s Family Fun Fest 2014 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3
... A long-running Merck ad featured an older woman with this message: ... be?" and recommended that women ask their doctors about bone ... Merck's drug Fosamax. But this very drug, (generic name alendronate) turned ... the risk of hip fracture from 2 percent to 1 percent, ...
... the time of Chaucer were not dwarfs but only short ... was the case with women more or less, a new ... revealed. ,As part of their study, scientists researched ... upon Humber, North East Lincolnshire, and found that the average ...
... engineered adult stem cells from human umbilical cord blood to ... type 1 diabetes by allowing people to grow their own ... ,The study was conducted by a team of researchers led ... Branch at Galveston. ,As part of the study, ...
... has decided to send youths to learn meditation from Indian ... visit to the war-hit country Thursday with a trip ... the Art of Living Foundation, Iraqi Youth Minister Jasin Mohammed ... of Iraq to Bangalore to undergo the group's Youth Leadership ...
... Abdul Kalam Friday urge the nation's doctors to work for ... Post-Graduate Institute of Medical Sciences in Rohtak, Kalam called upon ... ,If each doctor showed the zeal to treat at ... lot of diseases could be taken care of. ...
... by the American Academy of Neurology finds conventionally recommended ... system Lyme disease. However, there is no compelling ... in treating symptoms that persist following standard therapy. The ... edition of Neurology, the scientific journal of the American ...
Cached Medicine News:Health News:Women Urged to Be Wary of Ads Promoting Unwanted Drugs 2Health News:Women Urged to Be Wary of Ads Promoting Unwanted Drugs 3Health News:Our Medieval Ancestors Were More or Less Similar to Us Than Previously Thought 2Health News:Art of Living Foundation to Train Iraqi Youths 2Health News:Antibiotics Highly Effective for Treating Lyme Disease 2
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- "Australia Capsule Endoscopy Systems ... the Australia Capsule Endoscopy Systems market. The report provides ... and average prices (in US dollars) within market segments: ... , Capsule Endoscopes , Capsule Endoscopy Data ... The report also provides company shares and distribution shares ...
(Date:7/25/2014)... 25, 2014 /PRNewswire-iReach/ -- ScriptPro, of ... Powers Lake, Wisconsin , announce that ... and co-marketing agreement allowing ScriptPro to bring TCGRx ... the United States . ScriptPro is ... workflow systems to retail and ambulatory pharmacies. TCGRx ...
(Date:7/25/2014)... , July 25, 2014 GrowBLOX Sciences, Inc. ... binding Memorandum of Understanding ("MOU") with LaurelCo, LLC, an ... the acquisition of both cultivation and dispensary medical marijuana licenses ... to the MOU, GBLX will acquire a 20% equity interest ... proprietary GrowBLOX TM growing chambers, as well as all ...
Breaking Medicine Technology:Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 3Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 4Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 5ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3
... Texas--(BUSINESS WIRE)--Apr 3, 2007 - Repros,Therapeutics Inc. (NasdaqGM:RPRX) ... of Proellex(TM), an oral drug being developed to,relieve ... with Proellex results in a statistically highly,significant improvement ... well tolerated., Study Details and Results , This ...
... 03, 2007,/PRNewswire-FirstCall/ -- Cell Genesys, Inc. today ... Phase 2 trial of GVAX,immunotherapy for prostate ... in 80 patients with metastatic,hormone-refractory prostate cancer ... received the dose that is comparable to ...
Cached Medicine Technology:Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 2Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 3Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 5Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer 2Cell Genesys Provides Final Median Survival Data From Second Phase,2 Trial of GVAX Immunotherapy for Prostate Cancer 3
... provides standardized glare testing. It can be used ... the evaluation of glare disability. For cataract documentation, ... simulate two on-coming halogen car headlights as seen ... can be adjusted to simulate other glare conditions, ...
Aluminum english and metric ruler. 1 3/8 inche wide....
Ruler S/Steel....
At 14 cm point, ruler is bent at 90 degrees angle brought to a blunt point at 15 cm....
Medicine Products: